  Switch maintenance therapy , using alternative agents that were not administered during induction chemotherapy , is a treatment option for advanced non-squamous non-small cell lung cancer ( NSCLC). Bevacizumab is known to increase the efficacy of other chemotherapeutic agents; however , switch maintenance therapy with docetaxel and bevacizumab has not been adequately studied. The goal of this study was to evaluate the efficacy and safety of switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin , pemetrexed , and bevacizumab. Chemotherapy-na√Øve non-squamous NSCLC patients received induction therapy of four cycles of cisplatin ( 75 mg/m